2Seventy Bio's Phase 1 Trial Of The Plat-08 Study Of SC-DARIC33 In Acute Myeloid Leukemia Has Been Paused In Response To A Recent Grade 5 (Fatal) Serious Adverse Event And Was Followed By The Required Notification To FDA
Portfolio Pulse from Benzinga Newsdesk
2Seventy Bio's Phase 1 trial of the PLAT-08 study of SC-DARIC33 in acute myeloid leukemia has been paused due to a fatal serious adverse event, followed by the required notification to the FDA.
June 14, 2023 | 11:05 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
2Seventy Bio's Phase 1 trial of SC-DARIC33 has been paused due to a fatal serious adverse event, potentially impacting the company's stock price.
The pause in 2Seventy Bio's Phase 1 trial of SC-DARIC33 due to a fatal serious adverse event is a significant setback for the company. This news may negatively impact investor sentiment and lead to a decline in the stock price of TSVT in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100